Phaseline

Targets › AP4M1

AP4M1 (AP-4 complex subunit mu-1): drug programs, companies and trials

1 program from 1 company in 3 trials: 2 Phase 1, 1 Phase 3; Neurology; next expected readout Oct 2028.

Component of the adaptor protein complex 4 (AP-4). Adaptor protein complexes are vesicle coat components involved both in vesicle formation and cargo selection. (UniProt, O00189)

Open in Phaseline: the race on AP4M1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Elpida Therapeutics SPCMELPIDA
Recombinant adeno-associated virus serotype 9 (AAV9) encoding codon-optimized human AP4M1
AP4M1Phase 3Hereditary Spastic Paraplegia Type 50; Spasticity, Muscle; Spastic Paraplegia Type 50Oct 2028

Conditions

Hereditary Spastic Paraplegia Type 50 (1) Spasticity, Muscle (1) Spastic Paraplegia Type 50 (1)

Modalities

other (1)

Companies

Elpida Therapeutics SPC (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.